MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.70904

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2026

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Yagüe Caballero Carmen, García López Santiago, Royo Esteban Ana, Figueras Panillo Laura, Nos Pilar, de Castro Luisa, Martín-Arranz M Dolores, Barreiro-de Acosta Manuel, Ricart Elena, de Francisco Ruth, Iglesias Eva, Giordano Antonio, Varela Pilar, Rodríguez-Lago Iago, Rivero Montserrat, Sicilia Beatriz, Navarro-Llavat Merce, Vera Isabel, Suria Carles, Guardiola Jordi, Barrio Jesús, Calafat Margalida, Gutiérrez Ana, Calvet Xavier, de la Cruz David Rafael, Mesonero Francisco, Martínez Pascual Cristina, P Gisbert Javier, Gargallo-Puyuelo Carla J, Monfort I Miquel David, Sierra Mónica, Arranz Laura, Rodríguez-Gutiérrez Cristina, Lorente Rufo, Bermejo Fernando, Márquez-Mosquera Lucía, Torres Vicente Gisela, Pérez-Calle José Lázaro, Huguet José M, Ramos Laura, Ponferrada-Díaz Ángel, Ceballos Daniel, Diz-Lois Palomares Mª Teresa, Sesé Abizanda Eva, Vega Pablo, Pajares Ramón, Santos Fernández Javier, Betoré Elena, Busquets David, Merino Olga, Martínez-Flores Carlos, Zabana Yamile, Sampedro González Manuela Josefa, Ortiz de Zarate Jone, Fuentes Coronel Ana, Sainz Arnau Empar, Carpio Daniel, Jiménez Nuria, Marín-Jiménez Ignacio, Bujanda Luis, Camargo Camero Raquel, Irabien Martín, Abanades Tercero María, Velayos Jiménez Benito, Robledo Andres Pilar, Trapero Ana María, Delgado-Guillena Pedro G, Hernández Villalba Luís, Menacho Margarita, Rull Murillo Nuria, Leal Carles, Alba Cristina, Gómez Espín Rosa, Lucendo Alfredo J, Van Domselaar Manuel, García Alles Laura, Iyo Miyashiro Eduardo, Crespo Catalá Ana, Gilabert Pau, Martín Rodríguez Daniel, Navas-López Víctor Manuel, Calvo Iñiguez María, Ginard Daniel, Martínez Pérez Teresa, Domènech Eugeni, Casas Deza Diego

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The expanding use of targeted therapies in inflammatory bowel disease has made treatment sequencing increasingly relevant, yet evidence on anti-TNF effectiveness after prior biologics with different mechanisms of action (MOA) remains limited. Our objective is to evaluate the durability of anti-TNF treatment in this scenario.

METHODS

Multicentre study based on data from the ENEIDA registry. Patients who received second-line anti-TNF therapy after a first biologic with a different MOA for active luminal disease were identified. Using propensity score matching, each case was matched with three controls from two cohorts: patients treated with second-line anti-TNF after another anti-TNF and patients receiving first-line anti-TNF therapy. Treatment durability and short- and long-term clinical effectiveness were assessed.

RESULTS

Sixty-six Crohn's disease patients and 117 UC patients receiving anti-TNF after other MOA were included. In CD, second-line anti-TNF therapy after a different MOA (62% ustekinumab) was associated with a higher risk of treatment discontinuation compared with first-line anti-TNF therapy (HR 1.55; 95% CI, 1.05-2.30), without significant differences in short- or long-term clinical effectiveness. In UC, anti-TNF therapy after a different MOA (90% vedolizumab) was associated with lower treatment durability compared with first-line anti-TNF therapy (HR 1.69; 95% CI, 1.31-2.19) and with anti-TNF after another anti-TNF agent (HR 1.91; 95% CI, 1.48-2.48), its remission rates significantly lower at both short- and long-term follow-up (p < 0.001).

CONCLUSIONS

Anti-TNF therapy used after a different MOA is associated with reduced effectiveness and durability compared with its use as first-line therapy or after another anti-TNF agent, especially in UC.

Для цитирования: Yagüe Caballero Carmen, García López Santiago, Royo Esteban Ana, Figueras Panillo Laura, Nos Pilar, de Castro Luisa, Martín-Arranz M Dolores, Barreiro-de Acosta Manuel, Ricart Elena, de Francisco Ruth, Iglesias Eva, Giordano Antonio, Varela Pilar, Rodríguez-Lago Iago, Rivero Montserrat, Sicilia Beatriz, Navarro-Llavat Merce, Vera Isabel, Suria Carles, Guardiola Jordi, Barrio Jesús, Calafat Margalida, Gutiérrez Ana, Calvet Xavier, de la Cruz David Rafael, Mesonero Francisco, Martínez Pascual Cristina, P Gisbert Javier, Gargallo-Puyuelo Carla J, Monfort I Miquel David, Sierra Mónica, Arranz Laura, Rodríguez-Gutiérrez Cristina, Lorente Rufo, Bermejo Fernando, Márquez-Mosquera Lucía, Torres Vicente Gisela, Pérez-Calle José Lázaro, Huguet José M, Ramos Laura, Ponferrada-Díaz Ángel, Ceballos Daniel, Diz-Lois Palomares Mª Teresa, Sesé Abizanda Eva, Vega Pablo, Pajares Ramón, Santos Fernández Javier, Betoré Elena, Busquets David, Merino Olga, Martínez-Flores Carlos, Zabana Yamile, Sampedro González Manuela Josefa, Ortiz de Zarate Jone, Fuentes Coronel Ana, Sainz Arnau Empar, Carpio Daniel, Jiménez Nuria, Marín-Jiménez Ignacio, Bujanda Luis, Camargo Camero Raquel, Irabien Martín, Abanades Tercero María, Velayos Jiménez Benito, Robledo Andres Pilar, Trapero Ana María, Delgado-Guillena Pedro G, Hernández Villalba Luís, Menacho Margarita, Rull Murillo Nuria, Leal Carles, Alba Cristina, Gómez Espín Rosa, Lucendo Alfredo J, Van Domselaar Manuel, García Alles Laura, Iyo Miyashiro Eduardo, Crespo Catalá Ana, Gilabert Pau, Martín Rodríguez Daniel, Navas-López Víctor Manuel, Calvo Iñiguez María, Ginard Daniel, Martínez Pérez Teresa, Domènech Eugeni, Casas Deza Diego. Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.. Alimentary pharmacology & therapeutics. 2026. DOI: 10.1111/apt.70904.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.